A First-In-Human (FIH) Phase 1/2 Study To Assess Safety, Tolerability, And Preliminary Anti-Tumor Activity Of REGN7945, An Anti-CD38 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, In Combination With Linvoseltamab, An Anti-BCMA x Anti-CD3 Bispecific Monoclonal Antibody, In Participants With Relapsed/Refractory Multiple Myeloma. (NCT06669247)
Regeneron
This trial is Currently recruiting
Registration number NCT06669247
Program & service
This trial is being run with the Cancer service, and as part of the Haematology program.
Trial phase
Phase 1
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principle investigator
Professor Andrew Spencer
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTRIf you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.